Nektar Therapeutics reported one‑year maintenance data showing that monthly and quarterly dosing of rezpeg preserved stringent skin‑lesion improvements in 71% and 83% of patients with moderate‑to‑severe atopic dermatitis, respectively. The maintenance study met expectations and positions rezpeg as a competitive biologic against established therapies such as Dupixent, with the company highlighting less frequent dosing as a potential clinical differentiator. Company clinicians emphasized competitive efficacy and the drug’s dosing cadence as commercial advantages.